Authors
Fei Li, Chun-Xia Luo, Xing Ji, and Dong-Ya Zhu
Summary
Disrupting the nNOS–PSD95 interaction could selectively inhibit the NMDARs-nNOS signal pathway, without blocking NMDARs function and catalytic activity of nNOS, thereby sparing unwanted effects on many other important physiological processes mediated by the NMDARs and nNOS. In this protocol, 4-(3,5-Dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid, a nNOS-PSD95 interrupter, we named it ZL006, was prepared by the condensation of 3,5-dichlorosalicylaldehyde and 4-aminosalicylic acid, and the reduction of the condensation production with sodium borohydride. We synthesized the derivatives of ZL006 also.Further details
The protocol was published on Protocol Exchange on 6 January 2011. To see the entire protocol, click on the source link.Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 458
- Comments 0